GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Degree of Financial Leverage

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Degree of Financial Leverage : 0.00 (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Alseres Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Jun. 2014 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Alseres Pharmaceuticals's Degree of Financial Leverage or its related term are showing as below:

ALSE's Degree of Financial Leverage is not ranked *
in the Biotechnology industry.
Industry Median: 0.96
* Ranked among companies with meaningful Degree of Financial Leverage only.

Alseres Pharmaceuticals Degree of Financial Leverage Historical Data

The historical data trend for Alseres Pharmaceuticals's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals Degree of Financial Leverage Chart

Alseres Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alseres Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alseres Pharmaceuticals's Degree of Financial Leverage

For the Biotechnology subindustry, Alseres Pharmaceuticals's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alseres Pharmaceuticals's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's Degree of Financial Leverage falls into.



Alseres Pharmaceuticals Degree of Financial Leverage Calculation

Alseres Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Jun. 2014 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -100 (Jun. 2014) / -350 (Jun. 2013) - 1 )/( -0.539 (Jun. 2014) / -1.402 (Jun. 2013) - 1 )
=-0.7143/-0.6155
=1.16***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Alseres Pharmaceuticals  (OTCPK:ALSE) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Alseres Pharmaceuticals Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466
Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Executives
Mark Jerome Pykett officer: President and COO 223A MAIN ST, BOXFORD MA 021921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Peter G Savas director, officer: Chief Executive Officer 110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston director C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr officer: Exec VP of Fin & Admin & CFO C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon officer: Chief Financial Officer 1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck director P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines